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Deriving Measures of Intensive Care Unit Antimicrobial Use from
Computerized Pharmacy Data: Methods, Validation,
and Overcoming Barriers
David N. Schwartz, MD;1 R. Scott Evans, MS, PhD;2,3 Bernard C. Camins, MD, MSCR;4 Yosef M. Khan, MD, MPH;5
James F. Lloyd, BS;2 Nadine Shehab, PharmD, MPH;6 Kurt Stevenson, MD, MPH;5 for the
Centers for Disease Control and Prevention Epicenter Program
objective. To outline methods for deriving and validating intensive care unit (ICU) antimicrobial utilization (AU) measures from
computerized data and to describe programming problems that emerged.
design. Retrospective evaluation of computerized pharmacy and administrative data.
setting. ICUs from 4 academic medical centers over 36 months.
interventions. Investigators separately developed and validated programming code to report AU measures in selected ICUs. Use of
antibacterial and antifungal drugs for systemic administration was categorized and expressed as antimicrobial-days (each day that each
antimicrobial drug was given to each patient) and patient-days receiving antimicrobials (each day that any antimicrobial drug was given
to each patient). Monthly rates were compiled and analyzed centrally, with ICU patient-days as the denominator. Results were validated
against data collected from manual review of medical records. Frequent discussion among investigators aided identification and correction
of programming problems.
results. AU data were successfully programmed though a reiterative process of computer code revision. After identifying and resolving
major programming errors, comparison of computerized patient-level data with data collected by manual review of medical records revealed
discrepancies in antimicrobial-days and patient-days receiving antimicrobials that ranged from less than 1% to 17.7%. The hospital from
which numerator data were derived from electronic records of medication administration had the least discrepant results.
conclusions. Computerized AU measures can be derived feasibly, but threats to validity must be sought out and corrected. The
magnitude of discrepancies between computerized AU data and a gold standard based on manual review of medical records varies, with
electronic records of medication administration providing maximal accuracy.
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Antimicrobial resistance that renders previously treatable in-
fections unresponsive to most drugs is a significant and grow-
ing public health concern.1,2 This threat was recognized in
the most recent national action plan for the prevention of
healthcare-associated infections outlined by the Department
of Health and Human Services,3 and calls for a coordinated
national effort to monitor resistance and implement preven-
tion and control efforts have been long-standing.1,4 The In-
fectious Diseases Society of America and the Society for
Healthcare Epidemiology of America recently published
guidelines promoting the implementation of antimicrobial
stewardship interventions in hospitals.5 An integral compo-
nent of evaluating the impact of any of these strategies is the
accurate and continuous measurement of antimicrobial uti-
lization over time.
The increasingly computerized processes of health care de-
livery have made possible the automated acquisition of an-
timicrobial utilization data. Indeed, most modern hospitals
have universal computerization of laboratory, pharmacy, ad-
mission-discharge-transfer, and patient demographic and fi-
nancial data.
However, just as these data sources have been incorporated
into fully functional electronic health records for only a small
minority of hospitals,6 the derivation of reliable and accurate
reports based on computerized hospital data has generally
been difficult to achieve.7 Because these data are stored at
deriving antimicrobial use measures 473
























































































note. Medication ordering system describes physician orders; medication dispensing system describes pharmacy order entry. ADT,
admission-discharge-transfer; BJC, BJC Healthcare; BMT, bone marrow transplant; CARP, Chicago Antimicrobial Resistance Project; CCU,
coronary care unit; CPOE, computerized provider order entry; eMAR, electronic medication administration record; HELP, Health Evaluation
through Logical Processing; ICU, intensive care unit; IW, Information Warehouse; MCS, Medication Control System; MICU, medical ICU;
OSUMC, Ohio State University Medical Center; RSCU, respiratory special care unit; SICU, surgical ICU; SMS, Shared Medical Systems
Corporation; SQL, structured query language; STRI, shock-trauma-respiratory ICU; TICU, thoracic ICU.
a A change in the pharmacy system vendor during the study time period necessitated use of 2 data sources in this hospital.
each hospital or health system in disparate information sys-
tems, the procedures required for their collection, extraction,
cleaning, validation, and computation are often complex and
error prone.8 With regard to antimicrobial use measures spe-
cifically, published studies that have used electronic data
sources to derive these estimates have almost exclusively relied
on proprietary measurement systems, and the methods un-
derlying the acquisition, validation, and consolidation of such
data have not been well described.
We describe our efforts to demonstrate the feasibility and
validity of obtaining uniform measures of the use of anti-
microbials in selected intensive care units (ICUs) in 4 aca-
demic medical centers by accessing pharmacy and adminis-
trative data contained in computerized data warehouses.
Despite the considerable expertise and relevant experience of
the healthcare informatics specialists and investigators in this
study in accessing such data, we encountered a number of
problems that were largely unforeseen and therefore may be
informative to the development of a standardized approach
to deriving measures of antimicrobial use from electronic
data.
methods
Four tertiary care, academic medical centers were recruited
from institutions participating in the current Prevention Ep-
icenter Program,9 which is funded by the Centers for Disease
Control and Prevention, to participate in this study. The In-
stitutional Review Boards of each hospital approved our study
protocols and waived their requirements for patient and phy-
sician consent.
Hospital ICU Types and Information Technology
Resources
The characteristics of the participating facilities, respective
data warehouses, and medication ordering, dispensing, and
administration systems are outlined in Table 1. Descriptions
of these data warehouses have been provided elsewhere.8,10-12
Antimicrobial use data for selected ICUs in each hospital over
a 36-month time period (July 2004–June 2007) were acquired,
analyzed, and validated separately at each institution before
being sent to a single central epicenter (Chicago Epicenter
[D.N.S.]) for collation and final analysis.
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table 2. Numerators Used in Antimicrobial Utilization Measures and Their Definitions
Measure Definition Example
Antimicrobial-days Sum of the calendar days on which
each antimicrobial drug was
administered
2 drugs given for 5 days followed by a
different drug given for 5 days to 1
patient p 15 antimicrobial-days
Patient-days receiving antimicrobials Sum of the calendar days on which
one or more antimicrobial drugs
was administered
2 drugs given for 5 days followed by a
different drug given for 5 days to 1
patient p 10 patient-days receiving
antimicrobials
Antimicrobial starts Sum of the calendar days on which
each new antimicrobial drug was
started, following 3 or more days
without exposure to that drug
2 drugs given for 5 days followed by a
different drug given for 5 days to 1
patient p 3 antimicrobial starts
Antimicrobial courses Sum of the calendar days on which
any antimicrobial drug was started,
following 3 or more days without
exposure to any antimicrobial drug
2 drugs given for 5 days followed by a
different drug given for 5 days to 1
patient p 1 antimicrobial course
Defined daily doses (DDDs) World Health Organization–standard-
ized conversion of aggregate drug
dosing data into number of doses26
200 grams of vancomycin dispensed
divided by 2 grams per vancomycin
DDD p 100 DDDs of vancomycin
Antimicrobial use numerators (described below) were
computed from varying electronic data sources (Table 1). For
hospital A, whose pharmacy information system vendor
changed during the study period, the numerator data source
changed from pharmacy dispensing data to computerized
physician order entry (CPOE) data. Hospitals B, C, and D
obtained numerator data from electronic medication admin-
istration records (eMARs), pharmacy dispensing data, and
CPOE data, respectively. Although eMARs were used to doc-
ument medication administration in 3 of the 4 hospitals,
eMAR data were available in a format amenable to analysis
only at hospital B, which was able to distinguish antimicrobial
doses that were administered from those that were ordered
but were not administered for any reason (eg, because of
doses held or refused). Denominator data (ICU patient-days)
were derived from the same data sources as those from which
numerator data were computed in all hospitals, with the ex-
ception of Hospital A, where admission-discharge-transfer
data sources had to be queried separately after the change in
pharmacy information system vendors.
Antimicrobial Use Measures
The primary numerator measure for antimicrobial use was
antimicrobial-days, which is defined as calendar days on
which patients received each antibacterial or antifungal agent
by intravenous (IV) or oral administration. For example, 1
patient given 2 drugs for 5 days accrued 10 antimicrobial-
days. Drugs given in injectable, oral, or another systemically
administered form were counted only 1 time per day irre-
spective of route of administration. Secondary numerator
measures of antimicrobial use included patient-days receiving
antimicrobials, antimicrobial starts, antimicrobial courses,
and defined daily doses (Table 2). Our antimicrobial-days
have the same meaning as the “days of therapy” reported by
Polk and colleagues;13 however, we avoided this latter term
because of its resemblance to patient-days receiving antimi-
crobials. The programming logic used to compute numerator
events from the different data sources is summarized in Table
3. Antimicrobial use measures were summed in each ICU for
each calendar month over the study period and for each of
the antimicrobial agents and predefined drug classes (Table
4).
Antimicrobial use rates were calculated using ICU patient-
days as the denominator. An ICU patient-day was attributed
to each patient occupying an ICU bed at midnight of each
day, as previously recommended,14 so that events occurring
on the day of ICU admission were counted, while those oc-
curring on the day of ICU discharge were not.
Data Validation
The investigators participated in regular teleconference calls
to discuss problems with programming and data collection.
This provided a forum for shared learning, as problems en-
countered at one institution were evaluated in the context of
experience at the others. Inspection for face validity of data
derived from draft program code sometimes identified the
presence of programming errors before more detailed vali-
dation efforts were initiated, prompting detailed examination
of programming code to pinpoint and correct programming
flaws and subsequent validation studies to confirm data
validity.
Each hospital used 2 methods to systematically validate
their data. First, to measure how accurately medication ad-
ministration records reflected actual administration of med-
ication to patients, convenience samples of at least 100 in-
travenous antimicrobial doses that were scheduled for
administration in study ICUs were prospectively audited and
observed at patient bedsides for timeliness of administration,
using the method of Itokazu et al.15 The subsequent results
(timely dose administration or not) were compared with the
deriving antimicrobial use measures 475
table 3. Logic Used in Computing the Numerators Used in Antimicrobial Utilization Measures from Different Comput-
erized Data Sources
Data source Events measureda Logic applied
Pharmacy dispensing Antimicrobial doses dis-
pensed from pharmacy
One or more doses of each antimicrobial dis-
pensed during an ICU-day constitutes an an-
timicrobial-day; 1 or more doses of any anti-
microbial dispensed during an ICU-day
constitutes a patient-day receiving
antimicrobials.
Physician orders (CPOE) Antimicrobial start and stop
orders; days of admission
to and discharge from the
ICU
ICU-days on which each antimicrobial is or-
dered for continuous scheduled administra-
tion; subsequent ICU-days are counted as an-
timicrobial-days until either the
discontinuation of that drug or discharge
from the ICU. ICU-days on which any anti-
microbial is ordered and subsequent ICU-
days are counted as patient-days receiving an-
timicrobials until either the discontinuation
of all antimicrobials has been ordered or un-
til discharge from the ICU.
Medication administration (eMAR) Antimicrobial doses admin-
istered by a nurse
One or more doses of each antimicrobial ad-
ministered during an ICU-day constitutes an
antimicrobial-day; 1 or more doses of any
antimicrobial administered during an ICU-
day constitutes a patient-day receiving
antimicrobials.
note. CPOE, computerized provider order entry; eMAR, electronic medication administration record; ICU, intensive care
unit.
a Numerator events are counted only through the calendar day before discharge from the ICU.
table 4. Antimicrobial Classification System
Drug class Associated antimicrobial agents
Anti-pseudomonal Piperacillin-tazobactam, imipenem, meropenem, ceftazidime, cefipime, aztreonam, lev-
ofloxacin, ciprofloxacin, gentamicin, tobramycin, amikacin
Anti-MRSA Vancomycin (parenteral only), linezolid, daptomycin, quinopristin-dalfopristin
Anti-MSSA Oxacillin, nafcillin, dicloxacillin, clindamycin
Other b-lactam drugs Cefazolin, cephalexin, cefoxitin, ceftriaxone, penicillin, ampicillin, ampicillin-sulbactam,
amoxicillin, amoxicillin-clavulanate
Anti–Clostridium difficile Metronidazole (oral only), vancomycin (oral only)
Macrolide Azithromycin, clarithromycin, erythromycin
Tetracyclines Doxycycline, minocycline, tetracycline
Other antibacterials Metronidazole (parenteral only), moxifloxacin, trimethoprim, trimethoprim-
sulfamethoxazole
Antifungals Amphotericin B deoxycholate, liposomal amphotericin B, fluconazole, itraconazole,
voriconazole, caspofungin, anidulafungin
note. MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible S. aureus.
disposition of the dose as registered in the medication ad-
ministration records. Second, retrospective validation studies
were conducted by assembling cohorts of randomly selected
antimicrobial recipients from each of the ICUs during the
study period and comparing counts of numerator events
(compiled by applying draft computer queries to these co-
horts) with a manual review of the same patients’ medication
administration records, which is our gold standard. After
identifying and correcting programming errors, numerator
counts derived via revised program code and manual review
of medical records were applied to new cohorts of antimi-
crobial recipients, and results were compared until no new
programming errors could be identified.
results
Investigators at the 4 participating institutions were able to
generate antimicrobial utilization data for each of the selected
ICUs over the first 24 months of the 36-month study period,
and they reported preliminary intra- and inter-ICU antimi-
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table 5. Errors Encountered during Validation of Antimicrobial Utilization Rates Derived from Computerized Data Sources
Data source Error Cause Solution
Numerator data
1. Physician orders
(CPOE) Spuriously high rates of cefazo-
lin use in an ICU in hospital
A after a change to a new
pharmacy computer system.
Unbeknownst to study person-
nel, an automated testing
procedure added 233 cefazo-
lin-days over 7 months to
nonexistent patients.
Test entries were removed,
which resulted in revised
rates of cefazolin use that
were more comparable to
rates ascertained from data
from the older pharmacy
system.
2. Physician orders
(CPOE) Spurious increase in antimicro-
bial utilization rates in hospi-
tal A after change to new
pharmacy computer system.
Errant programming of ADT
data in the new system led to
an inappropriate attribution
of antimicrobial use following
patient transfer from the
ICU.
Programming was revised to
limit numerator events to
ICU patient-days as defined
by the ADT tables, and new
results were validated.
3. Pharmacy dispensing Patient-days receiving antimi-
crobials were calculated in-
correctly, with rates exceeding
the maximum 1,000 patient-
days receiving antimicrobials
per 1,000 ICU patient-days in
hospital C.
The programmer misunder-
stood the definition of pa-
tient-days receiving
antimicrobials.
Rates were corrected and vali-





administration (eMAR) Spuriously high antimicrobial
utilization rates in an ICU in
hospital B.
Communication error led to
programming of only antimi-
crobial recipients in the ICU,
rather than all patients in the
ICU, in computing denomi-
nator data.
Rates were reprogrammed to
include all ICU patients, and
new results were validated.
2. Pharmacy dispensing Spuriously low antimicrobial
utilization rates in a single
ICU in hospital C.
Summed denominator-days
from 2 parallel nursing units
comprising an ICU were used
to calculate antimicrobial use
rates for each nursing unit
instead of calculating denom-
inator ICU-days from each
nursing unit separately.
Rates were recomputed and val-
idated after the programmer
was made familiar with phys-
ical layout of the ICU.
note. ADT, admission-discharge-transfer; CPOE, computerized provider order entry; eMAR, electronic medication administration record;
ICU, intensive care unit.
crobial use rate comparisons.16 However, preliminary retro-
spective and prospective validation studies revealed major
discrepancies between numerator counts that substantially
biased the preliminary results and prompted careful review
of the code used in the computer queries for systematic error
by programmers and investigators. A summary of these pro-
gramming errors is provided in Table 5. These errors were
detected after findings of an inspection of the resulting reports
suggested a lack of face validity or after detection of incon-
sistencies between computerized reports of patient-level data
and recorded medication administration record entries dur-
ing retrospective validation.
After we identified and corrected all identifiable program-
ming errors, the numerator counts we derived via revised
program code and manual review of medical records were
applied to new cohorts of antimicrobial recipients, and results
were compared until no new programming errors could be
identified. The discrepancies between computer-derived and
manual counts of antimicrobial-days and patient-days re-
ceiving antimicrobials (presented in Table 6) reflect these final
comparisons. The retrospective validation studies revealed
variable levels of discrepancy by institution via numerator
counts derived from the application of final computer queries
and a manual review of medication administration records.
The overestimation of counts of antimicrobial-days and pa-
tient-days receiving antimicrobials that had been generated
deriving antimicrobial use measures 477
table 6. Retrospective Comparisons of Computerized Antimicrobial Numerator Data with Manual Review of Medical Records for




















Aa Pharmacy dispensing 100 661 613 7.8 385 408 5.6
A Physician orders (CPOE) 90 609 570 6.8 353 345 2.3
B Medication administration (eMAR) 100 4,551 4,509 !1 2,015 2,018 !1
C Pharmacy dispensing 100 1,792 1,523 17.7 953 832 14.5
D Physician orders (CPOE) 100 1,198 1,082 10.7 595 563 5.7
note. CPOE, computerized provider order entry; eMAR, electronic medication administration record.
a A change in the pharmacy system vendor during the study time period necessitated the use of 2 data sources in this hospital.
by computer code was less than 1% at hospital B, where
antimicrobial utilization rates were computed from eMAR
data. By contrast, programming of computerized pharmacy
dispensing data at hospital C, where delayed delivery of paper
medication orders from ICUs to the pharmacy may have led
to the dispensing of antimicrobials after orders for drug dis-
continuation or patient discharge were written,15 counted
17.7% more antimicrobial-days and 14.5% more patient-days
receiving antimicrobials than manual review of medical re-
cords did. Use of CPOE data to derive numerator antimi-
crobial measures at hospitals A and D generated intermediate
levels of discrepancy (Table 6).
Prospective bedside observations of the intravenous ad-
ministration of routinely scheduled antimicrobial doses re-
vealed more than 95% concordance between the observed
outcomes of dose administration events and the correspond-
ing dose administration statuses recorded in the MARs in
every ICU in this study (data not shown).
discussion
Our findings show that derivation of standardized patient-
level measures of antimicrobial utilization from a sample of
hospitals with disparate computerized pharmacy systems is
feasible. However, our experience highlights a few important
issues related to the use of computerized data sources to
derive and report hospital antimicrobial utilization rates.
First, interinstitutional differences in pharmacy computer
systems and available data sources (Table 1) necessitated the
use of institution-specific computing strategies (Table 3). This
contributed to varying levels of fidelity between antimicrobial
utilization results obtained by application of computer code
and results of manual reviews of patient records (Table 6).
Until greater uniformity among hospital data systems is
achieved or until valid antimicrobial use measurement pro-
grams are included in commercial and governmental hospital
pharmacy computer systems, institution-specific strategies for
data programming, validation, and interpretation will have
to be developed to ensure that accurate and comparable mea-
sures of antimicrobial utilization data are derived and re-
ported across hospitals.
Second, we found that programming antimicrobial utili-
zation measures on the basis of computerized pharmacy and
administrative data was complex and error prone. Despite
considerable experience in querying and analyzing comput-
erized data from our respective institutions,8,10-12 we made
important errors in our initial attempts to derive these mea-
sures of antimicrobial utilization (Table 5). Our need to adopt
separate, institution-specific computing strategies (Tables 1,
3), along with the complexities of computerized medical re-
cords in general17 and pharmacy data in particular,8 likely
contributed to these problems. However, many of the mis-
takes made stemmed from conceptual misunderstandings and
inadequacies in communication between clinician-investi-
gators and informaticists, and mitigation of these issues re-
quires careful application of basic tenets of multidisciplinary
collaboration and data review and validation (Table 7). The
use of complementary methods—that is, assessment of face
validity, review of procedures for developing computer code,
and retrospective validation procedures—were necessary to
fully identify and correct these errors, and this highlights the
importance of adopting a careful, systematic approach to col-
lecting and validating data from electronic health records.
Third, after maximally validating the program code in each
of our respective institutions, we measured variable levels of
overestimation of computed numerator counts against a gold
standard based on retrospective review of medical records
(Table 6). These discrepancies likely reflect interinstitutional
variation in efficiency and coordination of medication or-
dering, distribution, and administration procedures.15,18 In
particular, in hospital C, which had the most discrepancies,
delays to a centralized pharmacy in the transport of paper
orders for medication may have contributed to a delayed
response by the pharmacy to ordered changes in patient an-
timicrobial regimens, which then resulted in the pharmacy
dispensing to the ICU antimicrobial doses that were not ad-
ministered and that were therefore omitted from the MAR
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table 7. Potential Sources of Error in Computing Rates of Antimicrobial Use from Computerized Pharmacy Data and
Suggestions for Avoiding Them
Potential sources of error Suggested solutions
Data request/acquisition
Programmer’s understanding of clinical concepts
and goals underlying investigator’s request for
data may be incomplete Written request for data must clearly outline clinical concepts
and goals. Programmer should have frequent access to inves-
tigator to clarify conceptual issues.
Programmer’s understanding of the physical context
and clinical processes and procedures relevant to
the request for data may be incomplete The programmer should tour site(s) of care being studied. The
programmer should be oriented to the processes of care rele-
vant to the request for data (eg, hospital processes of medica-
tion ordering, distribution, and administration) emphasizing
the point(s) at which the computerized data being studied are
generated.
Investigator’s understanding of data structure and
programming procedures may be limited Programmer should describe proposed approach to request for
data, including anticipated shortcomings in data structure or
availability, to investigator before writing program code. Pro-
grammer should review program code with investigator be-
fore executing programming procedures.
Data analysis
Computerized data may require careful review for
outlier entries and may require reformatting (eg,
converting free text to categorical tabular entries)
before programming is possible Programmer should involve investigator in review of data tables
and obtain investigator’s guidance in interpreting outlier en-
tries. Magnitude of data cleaning and conversion efforts must
be estimated and the necessary resources—primarily, person-
nel time—allocated. Investigator must assist in designing data
restructuring plan and provide necessary nomenclature and
definitions.
Data validation
Investigator’s predisposition to trust integrity of
programming processes and data derived thereby
(“if it’s on a computer screen, it must be right”)
may be misguided Reports based on queries of computerized data must be care-
fully reviewed for face validity: Are all expected data elements
(eg, antimicrobial names) represented? Are results comparable
to previously validated data, if available? Do the results reflect
anticipated variation? Reports based on queries of computer-
ized data require validation, ideally via manual comparison of
samples of computerized data with an acceptable gold stan-
dard. Systematic sources of error must be vigorously sought
to explain recurring or substantial discrepancies in the results
of these comparisons.
(Tables 1, 3, 5). By contrast, the use of bedside recording of
eMAR data in hospital B for both computer-derived and
manually collected numerator data doubtlessly accounted for
the high affinity between the data obtained through these
different sources. Our results suggest that eMAR is the most
accurate source of pharmacy numerator data in the hospitals
in which it is in use; however, this finding requires confir-
mation from other institutions. Measures based on pharmacy
dispensing or physician orders, which are further removed
from the antimicrobial administration event, are more likely
to overestimate actual utilization.
The optimal metric for reporting hospital antimicrobial
utilization is unclear.19-23 We chose antimicrobial-days and
patient-days receiving antimicrobials (Table 2) as the primary
numerator measures because they provide complementary
information on the intensity and breadth of antimicrobial use
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in the ICU,23 they are minimally affected by variation in an-
timicrobial dosing regimens, and they should be readily ex-
tractable given the current widespread availability of detailed,
patient-specific computerized pharmacy data within hospitals
in the United States. Previous studies have used “days of
therapy,”13 which is analogous to our antimicrobial-days, to
rank and assess secular trends in antimicrobial utilization in
an alliance of 22 academic health centers and 130 hospitals
in the United States.24,25 However, those analyses were based
on charge and billing data, rather than the pharmacy dis-
pensing, physician order, or eMAR data that we employed.
Also, the specific methods—proprietary in one instance—
were not detailed and validation efforts were limited.24,25
Older surveys of antimicrobial utilization from the United
States and Europe that were performed where detailed, pa-
tient-specific data may not have been available have used
conversion factors such as the defined daily dose (DDD) and
the recommended daily dose26,27 to estimate patient-level an-
timicrobial use from aggregate antimicrobial use and census
data to make interinstitutional or international compari-
sons,27-29 analyze secular trends,29,30 and correlate antimicro-
bial use with antimicrobial resistance.31-33 However, pharmacy
reports of aggregate antimicrobial utilization may substan-
tially overestimate actual use in hospitals because of poorly
coordinated mechanisms of medication ordering, distribu-
tion, and administration.15 Moreover, DDDs underestimate
patient-level exposure to drugs that require renal dose ad-
justment,34 overestimate the use of antimicrobials for which
the conversion factor is lower than the doses that are com-
monly prescribed,13,35,36 and do not apply to most pediatric
patients.13
Adaptation of programming approaches to the disparate
information systems and data sources available in each in-
stitution will be a formidable challenge that will require un-
derstanding and the avoidance of potential errors that can
impede the valid and efficient measurement of antimicrobial
use. The Centers for Disease Control and Prevention is cur-
rently revising the data submission requirements for the An-
timicrobial Utilization component of the National Healthcare
Safety Network to receive standardized summary measures
directly from eMAR systems. This may represent the most
effective approach to achieving accurate centralized collec-
tion, analysis, and reporting of antimicrobial utilization mea-
sures from multiple institutions.37 Application of methods
similar to ours by these and other surveillance efforts will be
instrumental in achieving the widespread availability of valid
and efficient measurements of antimicrobial utilization.
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